PF-06843195 Prodrug

• CAT Number: I034506
• Molecular Formula: C20H26F3N8O7P
• Molecular Weight: 578.44
• Purity: 98%
• Synonyms: PF-06843195 Prodrug; PF06843195 Prodrug; PF 06843195 Prodrug
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 2,2-difluoroethyl (3S)-3-[[6-(2-aminopyrimidin-5-yl)-5-fluoro-2-morpholin-4-ylpyrimidin-4-yl]amino]-3-(phosphonooxymethyl)pyrrolidine-1-carboxylate
• InChI: InChI=1S/C20H26F3N8O7P/c21-13(22)9-37-19(32)31-2-1-20(10-31,11-38-39(33,34)35)29-16-14(23)15(12-7-25-17(24)26-8-12)27-18(28-16)30-3-5-36-6-4-30/h7-8,13H,1-6,9-11H2,(H2,24,25,26)(H,27,28,29)(H2,33,34,35)/t20-/m0/s1
• InChIKey: UCGFIRPRWMWKQG-FQEVSTJZSA-N
• SMILES: C1CN(C[C@@]1(COP(=O)(O)O)NC2=NC(=NC(=C2F)C3=CN=C(N=C3)N)N4CCOCC4)C(=O)OCC(F)F

PF-06843195（Cat No.:I034506）is a prodrug of a selective histamine H3 receptor antagonist. It is designed to target the H3 receptor, a key regulator of neurotransmitter release in the brain, with potential applications in treating cognitive impairments, sleep disorders, and other central nervous system (CNS) conditions. As a prodrug, PF-06843195 is metabolized into its active form after administration, optimizing its bioavailability and reducing the potential for side effects. Research has focused on its potential to improve wakefulness, attention, and overall cognitive function, though clinical trials are ongoing to assess its full therapeutic potential.